RE:Good discussionQuentin,
Thanks for your estimates and your perspectives.
From my perspective, the potential for use of pela in panc and other colorectal indications (we are waiting on the latter data) as well as mBC, as well as for adjuvant purposes with an array of I/O treatments means that I am not worried about multiplying price times quantity in any one context.
If there is a buyout, it will be substantial. For me, 2.25 bil is certainly substantial enough to solve all my problems and allow a great life in the remaining time I have here. Higher numbers would of course be better, but my kids are doing well on their own anyway. So I am just hoping that there actually is a buyout, which I as I said, I believe is being negotiated now.